Good morning, everyone, and welcome to The a2 Milk Company's Annual General Meeting for 2026. My name is Pip Greenwood, and I am honored to serve as the chair of your board. It is a pleasure to have shareholders joining us here, both in the room and online. I can confirm that a quorum is present. I now formally declare this meeting open. Before I start with some few introductory words, I would like to introduce my fellow directors and management who are here with me today. To my right, we have David Bortolussi, David Muscat, Grant Dempsey. To my left, we have Kate Mitchell, who we will hear from later, Lain Jager, Sandra Yu, and Antonio Rivera, who is known to us as Tonet.
Also present today is our company secretary, our auditors from Ernst & Young, and our external legal advisors, and our share register, MUFG Pension & Market Services. Today, you will hear from me as chair of the board and from our CEO, David Bortolussi. After this, we will then put forward the resolutions as described in the notice of meeting and respond to questions put to us by shareholders. With the formalities taken care of, it is now my pleasure on behalf of the board to update our shareholders on The a2 Milk Company's progress over the last year. FY 2026 was a landmark year for the company, underpinned by the acquisition of a2 PÅkeno, an advanced nutritional manufacturing facility located in the North Island of New Zealand, which has strengthened our supply chain and advanced our China growth strategy.
The acquisition has provided the company with increased capacity and resilience while enhancing our access to the attractive China label infant milk formula market through two existing China label registrations, and we saw a picture of those in the presentation that we have just seen. Since announcing the acquisition, we have received approval in China for those registrations to use the a2 brand and have subsequently launched those two China label infant formula products into the market. In addition, we have commenced the insourcing of English label a2 Platinum manufacturing to our a2 PÅkeno facility. These are really important milestones in our manufacturing transition and China growth strategy. From a trading perspective, we entered the year with strong momentum and delivered a positive first-half result in February. The company was trading ahead of plan and achieving growth across all product categories and markets.
However, as we entered the fourth quarter, we experienced supply chain challenges largely outside of the company's control. That significantly affected product availability in China. During this period, we also managed a limited product recall in the U.S. While this was disappointing after such a strong start to the year, these events do not change our long-term strategy, our confidence in the strength of the brand, or the opportunities ahead. Despite these fourth-quarter challenges, the company delivered a solid result for the year with revenue of NZD 1.97 billion, up 12.4%, and reported net profit after tax of NZD 207.5 million, excluding a2 PÅkeno and one-off transaction costs. Underlying net profit after tax was slightly higher at NZD 235.8 million, up 7%, demonstrating the resilience and strength of the business.
Throughout the year, in addition to supply chain transformation, we continued to invest for sustainable growth through brand marketing, product innovation, and A1 protein-free science, while progressing important operational priorities across the business. Our infant milk formula business remains central to our strategy, with encouraging progress from a2 Genesis, our latest English label product, and in emerging markets such as Vietnam. We also advanced our broader innovation pipeline across all life stages, with recent product launches in our other nutritionals portfolio performing very well. In liquid milk, the business performed strongly in both ANZ and U.S., reflecting the growing relevance of our A1 protein-free proposition with consumers. We are also pleased to build brand visibility through initiatives, including becoming the first-ever dairy milk partner for the Australian Open, and we are looking forward to partnering with the Australian Open again next year in 2027.
Turning to sustainability, we continue to advance our agenda, recognizing that long-term performance depends on operating responsibility across our value chain. During the year, we made further progress embedding sustainability into the way we work, with an ongoing focus on climate and nature, thriving farms, sustainable packaging, responsible sourcing, and supporting the communities connected to our business. While there is more to do, we remain focused on practical action that strengthens our position and demonstrates the company's commitment to supporting the planet and the communities in which we operate. Turning to capital management, and from that perspective, the board remains focused on delivering returns to shareholders over time while maintaining balance sheet flexibility to manage risk and fund potential future investment.
In FY 2026, the company delivered total ordinary dividends for the year of NZD 0.21 per share, representing a payout ratio of 74% of net profit after tax from continuing operations. In addition, as foreshadowed back in August 2025, the board also declared a special dividend totaling NZD 300 million, equating to NZD 0.4136 per share. In total this year, the company has paid NZD 453 million in ordinary and special dividends, providing a significant return to shareholders. Looking ahead, FY 2027 is an important year for the company as we rebuild momentum in our China label, a2 Zhi Chu, continuing to advance our supply chain transformation program and support the in-market launch of our two new China label infant milk formula products I mentioned earlier.
The board believes the business is well-placed to build on its underlying strengths with a clear focus on disciplined execution, recovery in China, infant formula business, and operational priorities that will support long-term growth and value creation. Before I close, I would like to acknowledge the hard work, resilience, and commitment of our teams across Australia, China, New Zealand, the U.S., and Vietnam. FY 2026 has been another significant year for the business, and on behalf of the board, I thank all our teams for the focus, dedication, and care they have shown in continuing to deliver for customers, partners and shareholders. I would also like to thank you, our shareholders, for your continued support and investment in The a2 Milk Company. I will now invite David to address the meeting.
Good morning, everyone, and thank you for joining us here today at our annual meeting. My name is David Bortolussi. I am the Managing Director and CEO of The a2 Milk Company. Today, I will build on Pip's opening remarks and share with you some more detail on our strategic, operational and financial highlights from the past year and provide an update on our China infant milk formula recovery and our FY 2027 outlook. We delivered FY 2026 results in line with or slightly ahead of our updated guidance in April, with double-digit- revenue growth. Infant milk formula, which I will refer to as IMF, grew 5% at a flat China market, supported by strong English label growth, with China label sales significantly impacted by supply chain disruption in the fourth quarter.
Supply chain disruption had a material impact on China IMF product availability, performance, and supply chain costs, which impacted our second-half group sales and earnings. As you would expect, we have been executing a comprehensive recovery plan, which I will come back to later in the presentation. Other nutritionals grew significantly, up 42%, through innovation in kids, seniors, UHT, and supplements. Liquid milk grew as well, well above market at 22% in Australia and the U.S. Our commitment to innovation has resulted in the launch of a series of new products over recent years, which are making meaningful contributions to our growth. These new products accounted for more than 50% of our sales growth in FY 2026, with further launches occurring in FY 2027. We also advanced our supply chain transformation significantly through the divestment of MVM and the acquisition of a2 PÅkeno.
Finally, following regulatory approval of our two new China label registrations, we declared a NZD 300 million special dividend and recently paid our full-year ordinary dividend with an improved payout ratio. Turning to our financial summary. Revenue was up 12.4% to NZD 1.975 billion. Reported EBITDA was down 2.5% to NZD 284 million, which was impacted by supply chain disruption and expected a2 PÅkeno losses. On an underlying basis, excluding a2 PÅkeno, EBITDA was up 5.4%, and our EBITDA margin was 15.6%. From an earnings perspective, underlying net profit after tax and EPS were up 7% and 6.8% respectively. The next slide shows that our growth was broad-based across all geographic markets and product categories. China and other Asia grew 11%, ANZ 10%, and the U.S. over 28%. By product category, IMF was up 5%, liquid milk up 22%, and other nutritionals up 42%, excluding a2 PÅkeno sales.
I will now cover the supply chain disruption experienced in the fourth quarter. As outlined in previous market announcements, product availability was materially impacted by a number of factors, including strong demand in the preceding quarter, freight challenges, a significant production backlog at Synlait, extended product release time frames, and additional customs testing requirements. These factors were resolved, and key channels mostly restocked by the end of June of this year. However, during the period of in-market product availability issues, a large proportion of existing users were forced to switch to alternative brands, which, as you can see in the chart, significantly impacted our China label market share during the fourth quarter. Our ability to recover market share largely depends on our ability to regain past users, new user recruitment momentum, and the performance of our two new China label IMF products recently launched in the market.
Given the extended out-of-stock period, we expect recovery to be gradual as we rebuild our user base. We are taking a measured and disciplined approach, which balances user recruitment with protecting brand health and trade economics while reducing the risk of excess inventory and product freshness issues. Early progress has been positive, and we continue to focus on executing our recovery plan, which has four priorities: rebuilding brand trust, driving user recruitment, supporting our distributor and retailer ecosystem, and maximizing the performance of new product launches. We have completed our trust-building actions. These included introducing our market-leading traceability tool with batch-by-batch testing and amplifying the benefits of the tool and other product credentials through social media, PR, and independent endorsements. We have also executed past user win-back programs, ramped up investments in new user recruitment, and launched our two new China label products.
On that note, I would like to acknowledge the tremendous work by our amazing a2 team, our loyal distributors and customers, and particularly our strategic partner, China State Farm, for their incredible support throughout the disruption and the recovery period. Moving to the next page. Our increased brand investment and careful trade management are supporting our recovery. Brand sentiment and net promoter score are back to prior levels, and search activity on Red and e-commerce platforms is at or above prior levels. Importantly, our estimated China label consumer offtake has recovered to around 50% of pre-disruption levels, up from around 40% in August. We are supporting the trade ecosystem and have intentionally constrained distribution to about two-thirds of prior levels to support rate of sale at retail. While past user win-back is slowing, new user recruitment is building with conversion rates at or above prior levels.
Our new China label products, launched recently at the China International Import Expo, also expand our addressable market, helping us reach more consumers to support recovery. English label sales have been impacted by category performance, which has been softer following industry recalls, the indirect impact of our own USA label recall, the in-market transition of a2 Platinum to our new product, and lastly, a2 Genesis China importation requirements currently requiring parcel shipments from Hong Kong.
Sales are now stabilizing, and new user recruitment is improving. The recent launch of our upgraded a2 Platinum formulation at CIIE, with significant marketing campaign support planned for the second half, will support the recovery. Turning now to FY 2027 and the company's outlook. We expect revenue and EBITDA to grow in FY 2027, supported by increased contribution from product innovation and new markets, continued momentum in other nutritionals and liquid milk, and a2 Pokeno profitability improvement.
As previously outlined, we have been focused on executing our China IMF recovery plan, and we expect China label and English label IMF to recover gradually in FY 2027, supported by the launch of our two new China label products, the recent launch of our upgraded a2 Platinum product, and pending resolution of the China importation requirements currently impacting a2 Genesis. The transition of a2 Platinum manufacturing to our a2 Pokeno facility is on track and substantially progressed. The company now has greater clarity on the associated transition costs, with total one-off transformation costs expected to be approximately NZD 15 million in FY 2027, with no further costs expected in FY 2028. Whilst a range of outcomes is possible depending on the rate of recovery in IMF, the company currently expects revenue growth of mid-single-digit percent and underlying EBITDA margin percent, which excludes the transformation costs, to be approximately 15%.
Turning to the next page. Our strategy remains unchanged. We remain focused on capturing the full potential in China IMF, ramping up product innovation, entering new markets, and transforming our supply chain, all underpinned by our investment in brand, science and innovation capability. On the next slide, we just fell short of achieving our medium-term revenue ambition of NZD 2 billion this year and now expect to do so in FY 2027. Our market and category growth drivers remain on track, except for China label IMF, which has been impacted by supply chain disruption, as previously mentioned. Beyond our FY 2027 goals, we have significant growth opportunities to capture in our core business, adjacent categories, and new markets over the years ahead.
We've been addressing these opportunities over time and thought that it would be helpful to lay out the markets and categories we are focused on, the estimated size of the markets at retail, the addressable component, and our current share. Our product portfolio has expanded significantly through a focus on innovation, increasing from seven key products in FY 2021 to 32 by the end of FY 2027. In summary, we have a relatively low share in a substantial addressable market with plenty of growth opportunities to pursue over the longer term. Over recent years, we've been focused on expanding our product portfolio, supported by investment in innovation and product development capability, a2 PÅkeno, and building our network of strategic manufacturing partners. Slide 19 highlights the many new innovations coming to the market in FY 2027 and beyond, which we're very excited about.
In the first half of FY 2027, we have already launched two new China label products that expanded our China label portfolio from one product to three. We're also in the process of launching a significant update to a2 Platinum, and we'll be updating a2 Genesis shortly as well, alongside continued expansion in kids, seniors, and supplements categories. Turning now to the science that underpins our a2 brand proposition and innovation. We have continued to invest in R&D for more than 25 years, building scientific evidence around milk that is A1 protein-free. A highlight this year was our U.S. growth monitoring study, a key clinical requirement for the US FDA new infant formula application process. The study showed that infants consuming formula made with a2 Milk demonstrated appropriate growth and had a comparable safety profile to infants consuming conventional formula, which is the primary purpose of the study.
However, encouragingly, secondary analysis of the data showed that a 6% greater length and weight gain and a higher protein conversion efficiency versus the conventional infant formula. These findings were presented at the American Society for Nutrition annual meeting in July, and it's certainly something that we'll be exploring more over time. Moving to the next page, our new market strategy continues to progress with Vietnam starting to scale. Distribution has expanded to more than 3,500 stores, and sales grew strongly during the year. We're also continuing to assess and progress further opportunities across Southeast Asia and the Middle East, including the Philippines, Singapore, Malaysia, Indonesia, UAE and Saudi Arabia. Moving now to our supply chain transformation, as previously mentioned, during the year, we completed the acquisition of a2 PÅkeno, a world-class nutritional manufacturing facility, and the divestment of MVM.
Since acquisition, we have more than doubled our a2 PÅkeno team, delivered the first phase of our multi-year capital investment program on time and on budget, and secured registration amendments for two new China label products, all significant achievements. The site is on track to be marginally EBITDA positive in FY 2027, excluding one-off transformation costs, as we insource a2 Platinum and capture vertical margin benefits. All of our FY 2026 key milestones relating to English label transition, China label registrations, and facility upgrades were completed. FY 2027 metrics are on track with production and financials in line with plan. Finally, we continue to make good progress on sustainability, including commencing work to convert the a2 PÅkeno gas-fired boiler to an electrode boiler to support achievement of our Scope one and two net zero target by 2030.
We also established on-farm data collection approaches to increase the accuracy of our Scope three emissions reporting and awarded 27 new projects through our Farm Sustainability Fund. That brings me to the end of my presentation. I look forward to answering any questions you may have after the formal business section of the annual meeting or after the meeting closes, if you prefer. Thank you very much for your time. I will now hand back to our Chair, Pip.
Thanks, David. I saw some of you, one person in particular, taking some photos of the presentation. The presentation is actually available on the NZX. We have released it to the NZX, and it is also, I assume, on our investors section of our website if you wanted to have another look at it. I am conscious there is quite a lot of good detail in there that you might want to have a look at your leisure. Now we turn to the matters that require resolution at the meeting, as outlined in our notice of meeting, with a poll being conducted for each resolution. The poll will be conducted at the end of each resolution, and your ballot papers and online voting card will be collated by our share registry. The resolutions set out in the notice of meeting are considered as ordinary resolutions.
That means to be passed, they require the approval of a simple majority of votes by the shareholders entitled to vote and voting on the resolution. Shareholders here in Auckland, you will be able to cast your votes by filling out the ballot form that you received at the registration desk and which will be collated at the end of the formal part of this meeting. For those attending online, they will be able to vote by clicking the Get a Voting Card box on the online portal. If you require further information and guidance on the voting process, please refer to the notice of meeting. There will be an opportunity for shareholders to ask questions both on the resolutions being put to the meeting today and more generally at the end of formal business.
When I call for questions, for those of you who are attending in person, please raise your hand, and a microphone will be delivered to you. Please clearly state your name prior to asking your question. We will also be responding to questions from shareholders attending virtually via the online portal. For shareholders attending via that portal, please submit your questions on the resolutions or general business now so we receive them in plenty of time to address them at the appropriate time during this meeting. I would like to take this opportunity to remind everybody that this meeting is being webcast, so you will be heard by an audience outside of this room. If we are unable to get through all the questions today within the time allocated, we will respond individually after the meeting. We now move to the resolutions.
The first resolution relates to the auditor's fees and expenses. Pursuant to the New Zealand Companies Act, the company wishes to authorize the directors of the company to fix the fees and expenses of our company's auditor, Ernst & Young, for the ensuing year. Are there any questions in respect of this resolution? Do we have any questions in the room? No?
We have received an online question from Alex Ball. How long has the auditor, EY, been in place, and what process and plans are in place around putting the audit out to tender?
Thank you for that question. EY have been our auditors since 2001. We don't have any current plans to put the audit up to tender, but we do have a policy of rotation of audit partner, and our current audit partner is up for towards the end of his term, and we're in the process of interviewing and thinking about a further audit partner at EY. That term for audit partner is for five years. Have we got any further questions, Chante, from theâ
We also have a question from Eva Quiding. While this scenario may be rare, what happens when the resolution does not pass due to not receiving more than 50% of votes cast?
âI think we'd have to I don't know what happens in that situation, actually. I think we wouldn't be permitted to pay the auditors for their fees, so I think we'd have to continue on the arrangements that had been approved by the AGM last year, which we were, those fees were approved by. I would just like to say, my understanding is that the resolution has been passed by a significant majority, so it's not a situation that we're going to have to think about. I'm sure everybody in the room will be relieved by that. Is there any further questions online?
We have no further questions online.
Okay. I now propose that the directors of the company be authorized Sorry, we just Yes. I now propose that the directors of the company be authorized to fix the fees and expenses of the company's auditor, Ernst & Young, for the ensuing year, and I put the motion to vote. Thank you. That takes us to our second resolution, the re-election of Kate. The next resolution Sorry. Kate is retiring by rotation in accordance with the company's constitution and the NZX Listing Rules, and offers herself for reelection. The board recommends Kate to you as a non-executive independent director and unanimously supports her reelection. I will now invite Kate to address the meeting.
Thanks, Pip. Chair, fellow shareholders, ladies and gentlemen, I am pleased to stand for reelection as a Director of The a2 Milk Company, and I thank the Board for its support and recommendation. Serving on this Board over the last three years has been a great privilege. During that time, we have overseen a period of significant progress for the company while navigating a dynamic operating and regulatory environment. My professional background spans more than three decades in financial markets, risk management, and governance. Prior to becoming a professional Director, I held senior leadership positions with Deutsche Bank and Goldman Sachs in London, where I advised companies on capital and risk management and led teams across international markets. Today, I bring that experience to the Board, together with perspectives gained through governance roles across listed, private, and public sector organizations.
I also have the responsibility of chairing the Audit and Risk Management Committee at a2. In that role, my focus has been to support strong financial stewardship, effective risk oversight, and robust governance practices. Importantly, our task is not simply to oversee risk, but to help ensure the company can pursue growth confidently and responsibly. If reelected, I will continue to bring an independent perspective, rigorous financial and risk expertise, and a strong commitment to effective governance and long-term shareholder value creation. Thank you very much for your support.
Thanks, Kate. I now propose that Kate Mitchell be reelected as a Director of the company. Are there any questions from shareholders concerning this resolution? Have we got any questions in the room? No. Have we got any questions online?
We have an online question from Eva Quiding. Ms. Mitchell, what would you deem as the three biggest risk areas for the company since the last annual meeting? What was the learning, if any, taken from dealing with these challenges?
I don't know that there's been a dramatic change in the risk profile of the company since the annual general meeting per se last year. Continuing risks that we engage with on a regular basis include ensuring that we have a supply chain that's fit and appropriate to ensure that we have ample product and the right product to serve our markets. The acquisition of Pokeno has substantially assisted us in strengthening our resilience in that capacity. We have an ongoing challenge in relation to ensuring that we go to market with excellent products for our customer base, and we constantly strive to understand our customers' requirements and meet those and grow. I think, again, with the acquisition of Pokeno and two additional China registrations, we have had the great privilege of expanding our product base, which has de-risked that aspect.
Thirdly, I think one of the big risks that we have as a company is ensuring, given the specialist nature of the niche in which we operate, that we have the best people we can possibly acquire. We have been really privileged to build a team that is truly excellent in the market, and that is an ongoing watch out for us to make sure that we can retain and grow those people.
Thanks, Kate. Is there any further questions?
We have no further questions online.
Thanks, Chante. I now propose that Kate Mitchell be reelected as a director of the company, and I put the motion to vote. Thank you. Moving on to the next resolution three. To align with recent practices for New Zealand and Australian executive remuneration, the board has committed to submitting our CEO's long-term incentive grant plan as a resolution on an advisory basis and for the purposes of the NZX Listing Rules to the annual meeting, which is the subject of this resolution. The company's LTI plan is designed to reward performance in support of the achievement of the company's growth strategy by targeting profitable long-term revenue and EPS growth, which requires appropriate investment. An overview of the key terms of the proposed grant of rights to David is set out in some detail in the notice of meeting.
The board considers the performance hurdles of the LTI plan sufficiently challenging and aligns with shareholder value creation. The board recommends you vote in favor of this resolution, and we unanimously support this grant of performance rights to David Bortolussi. As noted in the notice of meeting, a voting exclusion applies to this resolution. Are there any questions from shareholders concerning this resolution? Do we have any in the room? No. Do we have any questions online?
We have a question from Alex Ball. With regard to a2 Milk's LTI scheme, to which this resolution is proposed to grant rights for the MD. Has the board or will the board consider the introduction of some form of total shareholder return measure, as is common in other listed company LTI schemes?
Thanks for this question, Alex. We have considered that in the past. The problem for a2 is that there are not any, many, or if any comparable companies that we could put in a basket for TSR return. That said, the board will continue to monitor whether the LTI scheme continues to be fit for purpose, which we are very confident it is today.
We have another question from Eva Quiding. Why will there be no retesting of performance if performance conditions are not met at the end of the performance period?
There is no retesting needed because if they are not met, then the vesting does not occur. There is no need for retesting. Any further questions?
We have a question from Stephen Mayne. We do not normally get a vote on these sorts of resolutions in New Zealand listed companies, unlike the system in Australia. Is this resolution because of some form of Australian requirement? Has there been a material protest vote against it, and did any proxy advisors recommend against?
This is a voluntary resolution that we thought was appropriate to put to our shareholders. It is not in response to any formal Australian requirement, as we are a New Zealand company, which I think I mentioned earlier in the meeting. We have not had any protest vote from our proxy advisors, and in fact, our proxy advisors have recommended in favor of all resolutions.
We don't have any further online questions.
Thank you. I now propose that the acquisition of performance rights by the company's Managing Director and CEO, David Bortolussi, by grant under the company's long-term incentive plan be approved, and I put the motion to vote. Thank you. That now concludes the resolutions presented to shareholders for vote. Please now submit your vote for each resolution. Please select for, against, or abstain. For those attending in person, representatives from our share register will now collect your voting cards. For those attending the meeting online, voting will close shortly. The results of the polls will be released to the NZX and ASX following this meeting. I'll just pause for a few moments so we can just allow the votes to be collated. Thank you, everyone. We now move to general business. I'd like to offer the opportunity for shareholders to raise any general questions.
I'll start with questions in the room. Please make your questions concise so everybody who wants to ask a question has an opportunity to do so. As I said earlier, if we're unable to get through all the questions today within the time allocated, we'll respond individually after the meeting. I'd now like to open the floor for any questions from shareholders. Do we have any questions in the room? We've got one over here.
Thank you. Michael Shroff, shareholder. You talked about, this might be for Mr. Bortolussi, but supply chain disruption and with the China label, and I see there were a number of factors that came into play, and one of them was customs clearance, which is a classic ploy. My question is, were you to some extent being shut out of the market? If so, to whose benefit?
Sorry, sir, what was your name?
Mr. Shroff.
Thank you for that question. I think I will get David, you are probably best placed to answer that.
Thanks for the question, Mr. Shroff. Sorry, is my mic on now? Yeah. As you said, there were a number of factors that impacted our supply chain disruption during the fourth quarter. In terms of what was happening in the globe at that time was that there were a number of recalls happening because of a contaminant in infant formula in different markets around the world called cereulide. There were no real test methods and levels and approach standardized at that time. So both in New Zealand and China, there was lots of evolution of that at the time. Both on the export and the import into China, that was what was slowing things up at the time, as testing was occurring by ourselves, by Synlait, by the regulators in both markets.
It was just a process to go through, and there wasn't laboratory capacity as well at the time. So it was a real bottleneck in getting product through the market. On top of all that, we had low system inventory at the time due to a backlog of orders from Synlait. So there's multiple factors that impacted the reasons why we were out of stock in market for two to three months. So it wasn't targeted at a2 in particular, it was an industry-wide issue.
Thank you for that question. We have another question down the back here.
Hi. Shareholder. Two questions, really, if that's okay. One, how does the shipping for you, for shifting product, simply for, you know, because of the price of fuel now, and also on the shipping side now, has it settled down a lot better now, or is there still a problem? Because, you know, you must ship like Fonterra, quite a big volume. Who do you sort of use? And maybe because you're reasonably big, you do get maybe a bit of priority, I don't know. And the other thing you haven't mentioned is 11, 11, or 11, you know, the Just recent, you know what I'm talking about.
Yeah. Sorry, sir, what was your name?
Joe Block.
That is all right, I can address that. Thank you for your question. So two questions. So on the shipping, maybe I will distinguish between ocean freight, air freight, sort of the inter-country shipping, and then also in-market distribution. On the shipping of product from New Zealand to our core market, China, I assume that you are referring to, the cost of that, I mean, it has increased because of fuel, but the relative impact per unit for us is quite manageable. The air freight costs increased a lot over the course of this calendar year, which we had to use a significant amount on to address the supply chain constraints that we had.
From an availability point of view, there were periods of time where the allocation of freight on ocean freight and also in air freight was difficult to manage, and we mentioned that just in terms of freight issues for us. But that is settled down now largely. So we are shipping either sea freight and a smaller amount of air freight on a regular basis, and that is all manageable at the moment. I will note that distribution costs in market, so that is typically road freight from manufacturing to customer warehouse, has increased quite significantly due to fuel surcharges, because of the Middle East conflict. And in particular in the U.S., that is impacting us quite a bit at the moment because we have, you know, a lot of product being shipped all over a large country.
Is that mainly because of the world milk?
No, it is mainly because of the fuel surcharge on the distribution costs. Milk costs around the world, pricing has increased a bit locally here, driven by an increase in the farm gate milk price in New Zealand. Milk prices do go up and down, but they have come up recently. Your second question was in relation to the Double 11 key sales event in China. We, like all brands, participate in that. But over the years, we have not sort of promoted heavily into that. I think going back a long time in a2's history, it was a bigger event, where we used to load in a lot more inventory with concentrated sales during that period. But of course, our category is not as expandable as most, because there is only so much infant formula you can consume.
It is actually better for us in the long term to actually manage the peak of that and not promote heavily there, because it just brings forward pantry loading of inventory as well, and you are discounting the price. We do not generally participate as heavily in relation to Double 11 on both China label or English label that the company may have done in the past.
Therefore, it goes through mainly all your distributed people in China, is that what you are saying? It is distributed more and more evenly?
Yeah, it follows our existing distribution channel. China label is through the All of that goes, first stage is through our China State Farm partner, then it goes to MBS or to second-tier distributors, and then to the mother and baby store channel. So that is the offline trade. And then you have the online trade, which is the major platforms. And the official business can be sold in market, in retail. The English label business is a cross-border protocol, mainly through the cross-border e-commerce protocols, CBEC, and that is through the major platforms as well. So it is sold through different. The Double 11 sales go straight through the normal channels that we do business with. It is just a key sales event that extends over about a period of four or five weeks now. Yeah.
Thank you. Any other questions in the room? I will turn to online.
We have an online question from Stephen Mayne. How many shareholders voted by proxy before this AGM, and how many have attended both in person and online? Will you publish the headcount data with the poll results so we can better understand retail voting sentiment and turnout, which would have been less than 5% of shareholders?
I have the information in relation to the proxies that we have received, which is 639 proxies equating to 541 million shares voted, representing 74% of our issued capital. I am not aware, though, of the breakdown between in person and online. Can you share that with us, Chante?
We have approximately 90 people online, and around 30 registrations from voting shareholders in the room with us today.
Thank you. I am not aware that we will be publishing headcount data. I do not think that is market practice.
We will publish the results of the voting following the meeting, but not the headcount data. It is not typical practice.
Thank you. Do we have any further questions?
We have a question from Susan Robinson. Looking out in the next two to five years, how large do you see the size of the business coming from Vietnam? Could Vietnam, along with Indonesia and the Philippines, reach or exceed the China business volumes? What are you doing differently in terms of strategy, marketing in the Vietnamese and Southeast Asia markets, and what have you learned from your entry into China?
Do you want to take that, David?
Got a few questions in that, but I am happy to.
[crosstalk]
Thank you, Susan Robinson, for asking that question. The first part of that relates to how large do you see the size of the business becoming in Vietnam? At the moment, the Vietnam market is probably our most attractive market outside of China. There are many characteristics of the Vietnam market that are interesting to us, and many parallels with the China market. There is a large number of newborns, over one million each year, a significantly increasing middle class, high willingness to pay for foreign brands, the competitive set is similar, et cetera. There are lots of reasons why the Vietnam market is attractive to us. At the moment, our sales in Vietnam are just over NZD 20 million. We have only entered the market really in the last 18 months, and it is developing quite rapidly.
I think if we get that right, it would be somewhere in the order of NZD 50 million-NZD 100 million over time, but it is too early to be more specific about that. The next part of that is, could Vietnam, along with other Southeast Asian markets, exceed the China business volumes over time? The other Southeast Asian markets we see as not having as great, at this stage, not having as great a potential of Vietnam. But collectively, they can be quite meaningful over time, particularly run through a distributor-based approach with limited investment in market, both in terms of marketing as well as resources on the ground, they can be quite profitable.
In aggregate, they could be meaningful in addition to Vietnam, but we do not see them exceeding the contribution that we get in sales and earnings from the China market, which is obviously very substantive to our business. What are we doing differently in Vietnam and Southeast Asian markets? Vietnam is probably the most focused. It is actually, it is similar in a way, because we are partnered with it is just more concentrated, because we are partnered with one distributor, who then is working with us to both expand offline as well as online. Probably the only main difference there is that the trade channels are a bit different. There is a more fragmented mother and baby store channel, less national key accounts, and the online ecosystem or platforms in Vietnam are different to the China ecosystem.
They are more familiar with what we have here in Australia for marketing purposes, like the Meta platforms of Facebook and Instagram, rather than China-based, JD, Tmall, Red, Douyin, et cetera. It is just slightly different, but generally it is the same approach to the market, building brand awareness, education on our products, trial, conversion, and building our user base over time.
Thanks, David. Thanks, Susan, for that question. I think, as a board, we are very focused on these other markets, and as David said, they could be meaningful over time. But I think it is important to recognize that China is 50% of the world's infant formula market, so it is a very significant market in its own right. Do we have any further questions, Chante?
We have no further online questions.
Oh, thank you. Ladies and gentlemen, I think this brings us to the end of the formalities. On behalf of the board, I would like to thank you once again for joining us today and engaging in these important matters for our business. Please feel free to join us for some refreshments just outside the room. There will be a drink and something to eat, and you can engage with any members of the board who are on stage. Thank you very much for coming. It is great to see you all here.